Lonza Group AG stock (CH0013841017): Is its biopharma contract dominance strong enough to unlock new

LabiotechLab Thread: integrating workflows to replace fragmented systems

10x Genomics Blog10x genomics CEO Serge Saxonov sells $709,057 in shares - Investing.com

10x Genomics Blog10x genomics president Hindson sells $283,399 in company stock - Investing.com

10x Genomics Blog10x Genomics (NASDAQ: TXG) CEO sells 28,893 shares under 10b5-1 tax-related plan - Stock Titan

10x Genomics Blog10x Genomics (TXG) officer sells 11,595 shares to cover RSU taxes - Stock Titan

Clinical OMICsPrecision, Gene-Edited Antimicrobial Targets Difficult-to-Treat E. Coli

Clinical OMICsLargest Rare Variant–Lipid Association Study Finds Heart Disease Targets

Clinical OMICsWomen’s Memory Decline Linked to ECM Changes from Brain Estrogen Loss

Clinical OMICsVirtual Reality Could Pinpoint Early Signs of Alzheimer’s

Clinical OMICsMyeloid Malignancy Testing: Insights from a Portuguese Reference Center

BioPharma DiveVerge, following trial failure, rebrands its AI drug discovery ambitions

BioPharma DiveFDA delays decision on AstraZeneca breast cancer pill